China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced one new supplementary approval for its gamma-aminobutyric acid type A (GABAA) receptor antagonist remimazolam tosylate. The approval, with the indication being sedation and anesthesia during non-tracheal intubation surgery / operation, marks the drug’s fourth market approval.
Previous Approvals and Clinical Studies
Remimazolam tosylate was first approved in China in December 2019 for sedation in routine gastroscopy. It subsequently gained approvals for sedation for colonoscopy and induction of general anesthesia in June 2020 and June 2022, respectively. The drug is currently undergoing clinical studies in local anesthesia, auxiliary sedation, sedation in the ICU, and more.
Competitive Landscape
Similar products include Humanwell Healthcare (Group) Co., Ltd’s (SHA: 600079) remimazolam (benzenesulfonate), a Category 1 chemical injectable approved as a sedative in support of bronchoscopy procedures. This new approval for Hengrui Pharmaceuticals further solidifies its position in the market for GABAA receptor antagonists, addressing significant unmet medical needs in sedation and anesthesia.-Fineline Info & Tech
